Sec Form 13G Filing - ADAR1 Capital Management LLC filing for - 2025-08-14

Insider filing report for Changes in Beneficial Ownership

  • Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
  • Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G



Comment for Type of Reporting Person:  Includes (i) 2,540 shares of common stock, $0.00001 par value per share ("Shares") of Cellectar Biosciences, Inc. (the "Issuer"), held by ADAR1 Partners, LP and (ii) 422 Shares held by Spearhead Insurance Solutions IDF, LLC as of June 30, 2025. As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. Based on 2,677,039 Shares outstanding following the closing of the offering ("Offering") disclosed in the Form 424B4 prospectus filed by the Issuer with the Securities and Exchange Commission on July 2, 2025 (assuming no exercise of the over-allotment option described therein and no exercise of any of the warrants in connection with the Offering).


SCHEDULE 13G



Comment for Type of Reporting Person:  Includes (i) 2,540 shares of common stock, $0.00001 par value per share ("Shares") of Cellectar Biosciences, Inc. (the "Issuer"), held by ADAR1 Partners, LP as of June 30, 2025. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP. Based on 2,677,039 Shares outstanding following the closing of the offering ("Offering") disclosed in the Form 424B4 prospectus filed by the Issuer with the Securities and Exchange Commission on July 2, 2025 (assuming no exercise of the over-allotment option described therein and no exercise of any of the warrants in connection with the Offering).


SCHEDULE 13G



Comment for Type of Reporting Person:  Includes (i) 2,540 shares of common stock, $0.00001 par value per share ("Shares") of Cellectar Biosciences, Inc. (the "Issuer"), held by ADAR1 Partners, LP and (ii) 422 Shares held by Spearhead Insurance Solutions IDF, LLC as of June 30, 2025. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. Based on 2,677,039 Shares outstanding following the closing of the offering ("Offering") disclosed in the Form 424B4 prospectus filed by the Issuer with the Securities and Exchange Commission on July 2, 2025 (assuming no exercise of the over-allotment option described therein and no exercise of any of the warrants in connection with the Offering).


SCHEDULE 13G




SCHEDULE 13G


 
ADAR1 Capital Management, LLC
 
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, Manager
Date:08/14/2025
 
ADAR1 Capital Management GP, LLC
 
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, Manager
Date:08/14/2025
 
Daniel Schneeberger
 
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, in his individual capacity
Date:08/14/2025
 
ADAR1 Partners, LP
 
Signature:/s/ Daniel Schneeberger
Name/Title:Manager of ADAR1 Capital Management GP, LLC, the General Partner of ADAR1 Partners, LP
Date:08/14/2025
primary_doc.xml